ALK-Abelló Feed

2025-12-19 22:47:01 Storaktionærmeddelelse

2025-12-19 22:47:01 Major shareholder announcement

2025-12-01 15:35:00 ALK udnævner Edward Jordan til ny direktør for de kommercielle aktiviteter i Nordamerika 233,60 DKK | +1,21% | 50,7 MDKK

2025-12-01 15:35:00 ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America 233,60 DKK | +1,21% | 50,7 MDKK

2025-11-12 17:22:26 Nine-month interim report (Q3) 2025 (unaudited) - English version only 230,00 DKK | +11,54% | 251 MDKK

2025-11-12 17:22:26 Nine-month interim report (Q3) 2025 (unaudited) 230,00 DKK | +11,54% | 251 MDKK

2025-11-12 17:16:59 ALK opjusterer forventningerne til 2025 230,00 DKK | +11,54% | 251 MDKK

2025-11-12 17:16:59 ALK upgrades its full-year outlook 230,00 DKK | +11,54% | 251 MDKK

2025-11-06 17:02:01 Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025 201,00 DKK | -1,28% | 24,7 MDKK

2025-11-06 17:02:01 Invitation til præsentation af ALK’s regnskab for de første ni måneder (Q3) 2025 torsdag den 13. november 2025 201,00 DKK | -1,28% | 24,7 MDKK

2025-09-17 09:44:00 ALK og GenSci indgår partnerskab om at udvide AIT-markedet i Kina 208,40 DKK | +0,68% | 115 MDKK

2025-09-17 09:44:00 ALK and GenSci partner to expand the AIT market in China 208,40 DKK | +0,68% | 115 MDKK

2025-09-08 14:22:09 Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray 201,80 DKK | -0,69% | 21,4 MDKK

2025-09-04 12:31:00 ALK udvider den øverste ledelse med regionale nøglemarkeder 205,60 DKK | +1,18% | 27,7 MDKK

2025-09-04 12:31:00 ALK expands the Executive Leadership Team to include key commercial regions 205,60 DKK | +1,18% | 27,7 MDKK

2025-08-21 07:30:46 Six-month interim report (Q2) 2025 (unaudited) - English version only 197,10 DKK | +4,90% | 85,3 MDKK

2025-08-21 07:30:46 Six-month interim report (Q2) 2025 (unaudited) 197,10 DKK | +4,90% | 85,3 MDKK

2025-08-14 14:57:02 Invitation til præsentation af ALK’s regnskab for første halvår (Q2) 2025 torsdag den 21. august 2025 183,70 DKK | +0,33% | 26,2 MDKK

2025-08-14 14:57:02 Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025 183,70 DKK | +0,33% | 26,2 MDKK

2025-08-12 14:45:29 ALK opjusterer forventningerne til omsætningen i 2025 183,40 DKK | +3,56% | 76,6 MDKK

2025-08-12 14:45:29 ALK upgrades its full-year revenue outlook 183,40 DKK | +3,56% | 76,6 MDKK

2025-07-21 12:25:52 ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system 192,80 DKK | -0,72% | 23,3 MDKK

2025-07-18 14:01:25 EURneffy® godkendt som den første nålefri behandling af anafylaksi hos voksne og børn i Storbritannien 194,20 DKK | +0,10% | 27,3 MDKK

2025-07-18 14:01:25 EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK 194,20 DKK | +0,10% | 27,3 MDKK

2025-06-26 09:17:27 First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany 184,90 DKK | +1,20% | 25,6 MDKK

2025-06-17 08:01:25 ALK’s tablet mod træpollenallergi godkendt til allergivaccination af børn fra fem år 180,50 DKK | -1,37% | 104 MDKK

2025-06-16 14:03:55 ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025 183,00 DKK | -1,35% | 25,7 MDKK

2025-06-04 16:48:53 ALK participates at Jefferies Global Healthcare Conference 2025 in New York 182,80 DKK | +0,61% | 30,7 MDKK

2025-05-08 16:28:06 ITULATEK® approved for treatment of children and adolescents in Canada 160,80 DKK | -0,12% | 36,2 MDKK

2025-05-06 07:30:00 Three-month interim report (Q1) 2025 (unaudited) - English version only 166,50 DKK | +4,72% | 121 MDKK

2025-05-06 07:30:00 Three-month interim report (Q1) 2025 (unaudited) 166,50 DKK | +4,72% | 121 MDKK

2025-05-02 13:59:00 ALK enters into neffy® co-promotion agreement in the USA 155,80 DKK | +1,70% | 54,3 MDKK

2025-05-02 13:59:00 ALK indgår co-promotion-aftale vedrørende neffy® i USA 155,80 DKK | +1,70% | 54,3 MDKK

2025-04-29 16:39:29 Invitation til præsentation af ALK’s regnskab for første kvartal 2025 tirsdag den 6. maj 2025 147,00 DKK | +1,24% | 35,4 MDKK

2025-04-29 16:39:29 Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025 147,00 DKK | +1,24% | 35,4 MDKK

2025-04-23 15:58:41 ITULAZAX®-tablet mod træpollenallergi godkendt til behandling af børn i Europa 147,60 DKK | +2,43% | 30,0 MDKK

2025-04-23 15:58:41 ITULAZAX® tree pollen tablet approved for treatment of children in Europe 147,60 DKK | +2,43% | 30,0 MDKK

2025-04-03 16:24:06 Tildeling af aktiebaserede langsigtede incitamentsinstrumenter til direktion og ledende medarbejdere 142,40 DKK | +0,92% | 23,0 MDKK

2025-04-03 16:24:06 Grant of share-based long-term incentive instruments to members of the Board of Management and key employees 142,40 DKK | +0,92% | 23,0 MDKK

2025-03-13 18:06:48 Generalforsamling i ALK-Abelló A/S afholdt den 13. marts 2025 142,50 DKK | +2,81% | 29,6 MDKK

2025-03-13 18:06:48 Annual General Meeting in ALK-Abelló A/S held on 13 March 2025 142,50 DKK | +2,81% | 29,6 MDKK

2025-03-07 14:34:50 ACARIZAX® approved in Canada for treatment of young children 143,20 DKK | +0,49% | 42,6 MDKK

2025-03-04 22:20:51 Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff 145,30 DKK | -2,81% | 52,3 MDKK

2025-03-04 22:20:51 Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer 145,30 DKK | -2,81% | 52,3 MDKK

2025-02-27 21:51:51 Den amerikanske lægemiddelmyndighed (FDA) godkender ODACTRA® til behandling af husstøvmideallergi hos yngre børn 153,10 DKK | -0,39% | 71,8 MDKK

2025-02-27 21:51:51 FDA approves ODACTRA® for the treatment of house dust mite allergy in young children 153,10 DKK | -0,39% | 71,8 MDKK

2025-02-21 15:59:53 Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer 158,10 DKK | +2,00% | 51,1 MDKK

2025-02-21 15:59:53 Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff 158,10 DKK | +2,00% | 51,1 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

ALK-Abelló

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden